Treatment outcomes for SDH-deficient gastrointestinal stromal tumors remain alarmingly poor compared to other GIST subtypes. Current standard therapies achieve response rates of just 12 percent in SDH-deficient cases, compared to 85 percent for KIT-mutant GIST and 70 percent for PDGFRA-mutant variants. This stark disparity underscores why precision medicine approaches are critical for this rare cancer subset. A phase 2 trial of rogaratinib, an FGFR inhibitor, now demonstrates encouraging efficacy in patients previously limited to ineffective treatment options. By targeting the distinct molecular mechanisms underlying SDH-deficient tumors, rogaratinib offers a potential breakthrough for a patient population that has historically experienced poor clinical outcomes.
Was this article helpful?
